RxDoctor Payments Data

Kayla Rokey

Nurse Practitioner · Spring Valley, ILNPI 1033746755

Payments from drug & device makers

$5,456in general payments, 2019–2025

Across 278 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$884
  • Astellas Pharma US Inc$802
  • Sumitomo Pharma America, Inc.$739
  • 180 Medical, Inc.$346
  • Axonics, Inc.$311
  • Olympus America Inc.$275
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,05793%
  • Education$3997%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,456 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$188,242
Medicare patients
1,021
Services billed
4,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron187$106,736
GemtesaVibegron124$105,743
Tamsulosin Hcl711$8,271
Mirabegron ErMirabegron12$5,678
Potassium Citrate ErPotassium Citrate65$5,605
Tolterodine Tartrate ErTolterodine Tartrate21$2,274
Oxybutynin Chloride ErOxybutynin Chloride109$2,223
Silodosin12$1,280
Solifenacin Succinate29$1,149
Bethanechol Chloride21$1,065
Ciprofloxacin Hcl185$941
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst57$916
Tolterodine Tartrate13$833
Alfuzosin Hcl ErAlfuzosin Hcl51$805
Desmopressin Acetate13$795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$802$106,736187 claims
Sumitomo Pharma America, Inc.Gemtesa$739$105,743124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Spring Valley

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →